ClinicalTrials.gg
Active, not recruitingNCT06844006ADMINISTER IIUpdated Oct 15, 2026

Investigating the Impact of Nudging Cardiologists to Prescribe Class I Recommendations Foundational- and Additional Medical Therapy in Heart Failure Patients

An interventional study of Nudging in Heart Failure, sponsored by Medisch Spectrum Twente. Active, not recruiting at 5 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Medisch Spectrum Twente · Not applicable, Interventional, and Treatment

How we know

Updated Oct 15, 2026Now Active, not recruitingStart date moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,320
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.

Enrollment
43rd of 234
1,320 · median 284
Started
2026
with 17 others
No phase
105 of 313
19 open now
Primary completion
2028-01
later than 49 of 79 live
Registered
286th of 313
by date

Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 43rd largest by enrollment of the 234 interventional ones that give a count, is one of 18 that started in 2026, is one of 105 with no phase, reaches primary completion later than 49 of the 79 other live ones, and was the 286th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:

52 more — sign in →

All 57 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Heart Failure with a site in Netherlands, or all of them as a file.
02

Study summary

This study investigates the impact of a nudge-based intervention on improving 2026 European Society of Cardiology guideline class I Foundational Medical Therapy (FMT) and Additional medical therapy (AMT) prescription among cardiologists. Using a stepped wedge randomized controlled trial design, we assess whether digital decision support-leveraging home monitoring and clinical data-enhances adherence to guideline-recommended medication titration. The primary outcomes include HF related hospitalization rates and all cause mortality.

03

Conditions studied

  • Heart Failure

Browse trials for

Keywords

  • Digitial Care
  • Home monitoring
  • Heart Failure
  • Nudging
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All heart failure diagnoses
  • >18 years

Exclusion criteria

Exclusion Criteria:

  • Not understanding the Dutch Language.
  • Allergies that make uptitration impossible.
  • Admission to hospice or palliative care.
  • Severe psychological disorders.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,320 participants (actual)

Study arms

  • Other
    Intervention

    All cardiologists will be nudged during the trial. with the use of a stepped wedge design there will be a structured embedding in the current standard of care.

    Combination Product: Nudging

Interventions

  • Combination productNudging

    Clinicians will be nudged with a prompt, including remote monitoring data, current medication data, contraindications, in the electronic patient dossier whether further optimization to class I 2026 ESC recommendations of FMT and AMT is possible.

06

What researchers measure

Primary outcomes

  1. HF related hospitalization

    The frequency of HF related hospitalization and duration of the hospitalization.

    Time frame: HF related hospitalization during the 15 month duration of the study.

  2. All cause death

    Time frame: All cause death rate during the 15 month duration of the study.

07

Study locations

5 sites
08

References and documents

Publications

  • Man JP, Koole MAC, Meregalli PG, Handoko ML, Stienen S, de Lange FJ, Winter MM, Schijven MP, Kok WEM, Kuipers DI, van der Harst P, Asselbergs FW, Zwinderman AH, Dijkgraaf MGW, Chamuleau SAJ, Schuuring MJ. Digital consults in heart failure care: a randomized controlled trial. Nat Med. 2024 Oct;30(10):2907-2913. doi: 10.1038/s41591-024-03238-6. Epub 2024 Aug 31. PubMed 39217271 ↗

Related links

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2028, 15 months after the start.

Of 1,119 non-industry interventional studies with no phase under Heart Failure, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 50. This study's planned 15 months is below that.

Counting every sponsor, half of 1,355 studies reached it within 31 months; a quarter within 16 and three quarters within 52.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Jun 2024 → Oct 2026, primary completion Mar 2028 → Jan 2028 and completion Aug 2028 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2025
First posted
Feb 25, 2025
StartActual
Oct 9, 2026was Jun 2024
Primary completionEst.
Jan 9, 2028was Mar 2028
CompletionEst.
Jul 9, 2028was Aug 2028
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 15, 2026
Start date
Jun 13, 2024→Oct 9, 2026
Oct 15, 2026
Primary completion
Mar 30, 2028→Jan 9, 2028
Oct 15, 2026
Study completion
Aug 31, 2028→Jul 9, 2028
Oct 15, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameHF related hospitalizationFrom enrollment to the end of the design (15 months). → HF related hospitalization during the 15 month duration of the study.
Oct 15, 2026
Title
Investigating the Impact of Nudging Cardiologists to Prescribe GuidelineClass I Recommendations Foundational-directed and Additional Medical Therapy in Heart Failure Patients
Oct 15, 2026
Sponsor
Collaborators added: Maasstad Hospital; collaborators removed: Maasstad Hospital, Rotterdam
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Enrolling by invitation→Active, not recruiting
    Start date Jun 13, 2024→Oct 9, 2026
    Primary completion Mar 30, 2028→Jan 9, 2028
    Study completion Aug 31, 2028→Jul 9, 2028
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameHF related hospitalizationFrom enrollment to the end of the design (15 months). → HF related hospitalization during the 15 month duration of the study.
    Sponsor Collaborators added: Maasstad Hospital; collaborators removed: Maasstad Hospital, Rotterdam
    Title Investigating the Impact of Nudging Cardiologists to Prescribe GuidelineClass I Recommendations Foundational-directed and Additional Medical Therapy in Heart Failure Patients
    + 3 other changes: verification date, description and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06844006
Lead sponsor
Medisch Spectrum Twente
Collaborators
Onze Lieve Vrouwe Gasthuis, St. Antonius Hospital, Catharina Ziekenhuis Eindhoven, Maasstad Hospital
Responsible party
Mark Schuuring (Assistent Professor M.J. Schuuring (M.D., Ph. D., FESC, FEACVI, FHFA), Medisch Spectrum Twente) — Principal investigator
First posted
Feb 25, 2025
Start date
Oct 9, 2026
Primary completion
Jan 9, 2028 (estimated)
Completion
Jul 9, 2028 (estimated)
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion